<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pain in children: Approach to pain assessment and overview of management principles</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pain in children: Approach to pain assessment and overview of management principles</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pain in children: Approach to pain assessment and overview of management principles</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie Hauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David G Poplack, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Assessment and management of pain are essential components of pediatric care. In children, especially young children, it can be challenging to identify the presence and severity of pain and then to treat the pain. The use of assessment tools based upon cognitive ability is important to ensure that children of all ages receive adequate pain control.</p><p>Assessment of pain and an overview of pain management in children will be reviewed here. Pain management for specific pediatric clinical settings and conditions are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal pain (see  <a class="medical medical_review" href="/d/html/5021.html" rel="external">"Assessment of pain in neonates"</a> and  <a class="medical medical_review" href="/d/html/5018.html" rel="external">"Management and prevention of pain in neonates"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedural pain management and sedation (see  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach"</a> and  <a class="medical medical_review" href="/d/html/85542.html" rel="external">"Procedural sedation in children: Selection of medications", section on 'Sedation for painful procedures'</a> and  <a class="medical medical_review" href="/d/html/82857.html" rel="external">"Pediatric procedural sedation: Pharmacologic agents", section on 'Analgesic agents'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perioperative pain (see  <a class="medical medical_review" href="/d/html/127173.html" rel="external">"Approach to the management of acute perioperative pain in infants and children"</a> and  <a class="medical medical_review" href="/d/html/94561.html" rel="external">"Pharmacologic management of acute perioperative pain in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of topical anesthetics in children (see  <a class="medical medical_review" href="/d/html/6338.html" rel="external">"Clinical use of topical anesthetics in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain management in children with sickle cell disease (see  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic abdominal pain (see  <a class="medical medical_review" href="/d/html/112.html" rel="external">"Functional abdominal pain in children and adolescents: Management in primary care"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain management following burn injury (see  <a class="medical medical_review" href="/d/html/16505.html" rel="external">"Paradigm-based treatment approaches for management of burn pain"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain in children at the end of life (see  <a class="medical medical_review" href="/d/html/6252.html" rel="external">"Pediatric palliative care", section on 'Management of end-of-life symptoms'</a>)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of pediatric pain includes determining the underlying type, source and location, and severity of pain.</p><p class="headingAnchor" id="H3"><span class="h2">Types of pain</span><span class="headingEndMark"> — </span>Pain can be defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage [<a href="#rid1">1</a>].</p><p>Pain can be classified as being nociceptive, neuropathic, or nociplastic [<a href="#rid1">1</a>]. Determining the type of pain helps in identifying the cause of pain, which may guide treatment choices. (See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain", section on 'Inferred pathophysiology and treatment implications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nociceptive pain</strong> is caused by stimulation of intact nociceptors as a result of tissue injury and inflammation  (<a class="graphic graphic_figure graphicRef63962" href="/d/graphic/63962.html" rel="external">figure 1</a>). It is divided into somatic pain with receptors in skin, soft tissue, skeletal muscle, and bone; and visceral pain with receptors in internal organs, such as the kidney and gastrointestinal tract. Somatic pain is well localized and described as sharp, aching, squeezing, stabbing, or throbbing. Visceral pain is typically poorly localized and is often described as dull, crampy, or achy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathic pain</strong> is caused by nerve injury (eg, resulting from compression, transection, infiltration, ischemia, or metabolic injury to the nerves). It is often described as burning, shooting, electric, or tingling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nociplastic pain</strong> is a third category that is mechanistically distinct from nociceptive and neuropathic pain and that occurs without evidence of tissue or nerve damage. The mechanisms that underlie this type of pain are not well understood. It is thought that augmented central nervous system pain and sensory processing and altered pain modulation (eg, enhanced central excitability and/or diminished central inhibition) play prominent roles [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Source and location</span><span class="headingEndMark"> — </span>Details of the primary disease may be helpful in determining the source and type of pain, which may guide management decisions.</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer – Children with cancer may have nociceptive somatic pain (as defined in the preceding section) from bone metastases or tumor, nociceptive visceral pain (eg, from hepatic distention and bowel wall edema), and neuropathic pain from tumor infiltration of peripheral nerves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Developmental impairment – Children with severe developmental impairment have nociceptive pain that may occur acutely from fractures, urinary tract infection, or pancreatitis or chronically from gastroesophageal reflex, constipation, positioning, or spasticity. Such children are also at risk for neuropathic pain as a result of visceral hyperalgesia, central neuropathic pain, and development of peripheral neuropathic pain following surgery [<a href="#rid3">3,4</a>]. (See <a class="local">'Neurologic impairment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedural and postoperative somatic pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell disease – Children with sickle cell disease often have acute nociceptive pain (ie, painful crisis) due to vaso-occlusive episodes. (See  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Acute painful episodes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pain – Chronic headaches, abdominal pain, and musculoskeletal pain require a comprehensive assessment; however, it often does not stem from an organic disease process [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/2842.html" rel="external">"Headache in children: Approach to evaluation and general management strategies"</a> and  <a class="medical medical_review" href="/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation"</a>.)</p><p></p><p>Localization of pain is also helpful in determining the etiology. There are separate topics that review the evaluation of pain in children for the following specific anatomical sites:</p><p class="bulletIndent1"><span class="glyph">●</span>Hip (see  <a class="medical medical_review" href="/d/html/2856.html" rel="external">"Approach to hip pain in childhood"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Back (see  <a class="medical medical_review" href="/d/html/2853.html" rel="external">"Back pain in children and adolescents: Evaluation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Chest (see  <a class="medical medical_review" href="/d/html/6469.html" rel="external">"Nontraumatic chest pain in children and adolescents: Approach and initial management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Joints (see  <a class="medical medical_review" href="/d/html/6405.html" rel="external">"Evaluation of the child with joint pain and/or swelling"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Abdomen (see  <a class="medical medical_review" href="/d/html/6454.html" rel="external">"Causes of acute abdominal pain in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation"</a>)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Severity assessment</span><span class="headingEndMark"> — </span>The goal of pain assessment is to identify pain, assess severity, and track the response to interventions. Postoperative pain management, for example, can be guided by self-reporting or with use of a pain assessment tool. Assessment of chronic pain involves identifying the frequency, duration, and severity of pain episodes. Parents and children can be asked to rate the severity of a typical episode using general categories (mild, moderate, severe) and how pain impacts daily function (attendance at school, play with friends). Pain assessment tools can be used to supplement this information.</p><p>In children, assessment of the severity of pain is performed by the following two methods [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Self-reporting</p><p class="bulletIndent1"><span class="glyph">●</span>Use of behavioral observational scales in patients who are unable to perform self-reporting</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Self-reporting</span><span class="headingEndMark"> — </span>Self-reporting relies upon the cognitive ability of the child to understand that his or her pain severity can be measured along a continuum [<a href="#rid6">6</a>]. In younger children, evaluation of pediatric pain typically uses age-based pain rating scales.</p><p class="bulletIndent1"><span class="glyph">●</span>Younger children (three to eight years of age) – Some children as young as three years of age are capable of quantifying their pain and translating it to a visual representation. In this age group, pain is quantified using visual analog pain scales based upon a series of faces showing an increase in distress or pain  (<a class="graphic graphic_figure graphicRef51021" href="/d/graphic/51021.html" rel="external">figure 2</a>) [<a href="#rid7">7-10</a>]. The reliability of pain assessment increases with age and the cognitive ability of the child.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older children (8 to 11 years of age) – Pain assessment in this age group is generally performed using visual analog tools that rate the intensity of pain on a horizontal or numeric scale (eg, 0 to 10 scale).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescents – Adolescents can rate their pain using a numerical rating scale without the use of an accessory pain assessment tool  (<a class="graphic graphic_form graphicRef50711" href="/d/graphic/50711.html" rel="external">form 1</a>). In this age group, a description of the following components of pain usually can be obtained from the history:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Description – Is the pain sharp, stabbing, dull, burning, or tingling?</p><p class="bulletIndent2"><span class="glyph">•</span>Location and radiation – Where does the pain start and spread to?</p><p class="bulletIndent2"><span class="glyph">•</span>Intensity – How would you rate your pain on a scale of 1 to 10?</p><p class="bulletIndent2"><span class="glyph">•</span>Duration and constancy – Is the pain steady or does it come and go?</p><p class="bulletIndent2"><span class="glyph">•</span>Frequency – How often does the pain occur?</p><p class="bulletIndent2"><span class="glyph">•</span>Factors that worsen or relieve pain – Is there anything that makes the pain better or worse?</p><p></p><p class="headingAnchor" id="H147230332"><span class="h3">Pain location tools</span><span class="headingEndMark"> — </span>Several graphic-based pain location tools have been used to determine the location of pain in children and adolescents, including the Adolescent and Pediatric Pain Tool and the Pediatric Pain Questionnaire. These tools typically use a graphic outline of the body, and the patient is asked to "color" in the areas where he or she is experiencing pain. A systematic review of the literature reported that although the quality of the studies included was not high, overall, there was moderate evidence that these tools reliably located pain in older children (average age of patients 10 years) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Observational tools</span><span class="headingEndMark"> — </span>The following observational tools are used to assess pain in infants and children who are unable to self-report. These pain scales are based upon scoring facial expressions, ability to be consoled, level of interaction, limb and trunk motor responses, and verbal responses [<a href="#rid6">6,12,13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Revised Face, Legs, Activity, Cry, Consolability (r-FLACC) tool  (<a class="graphic graphic_table graphicRef81819" href="/d/graphic/81819.html" rel="external">table 1</a>) [<a href="#rid14">14,15</a>] – Nonverbal children</p><p class="bulletIndent1"><span class="glyph">●</span>Non-Communicating Children's Pain Checklist-Postoperative Version (NCCPC-PV) [<a href="#rid13">13</a>] – Nonverbal children</p><p class="bulletIndent1"><span class="glyph">●</span>Nursing Assessment of Pain Intensity (NAPI) – Newborn to 16 years of age</p><p class="bulletIndent1"><span class="glyph">●</span>Paediatric Pain Profile (PPP) [<a href="#rid16">16,17</a>] – Nonverbal children</p><p class="bulletIndent1"><span class="glyph">●</span>Individualized Numeric Rating Scale (INRS) [<a href="#rid18">18</a>]</p><p></p><p>In a study that compared the r-FLACC, NCCPC-PV, and NAPI assessment tools, the r-FLACC received the highest clinical utility score, followed by the NAPI [<a href="#rid19">19</a>]. Based upon the limited data, no tool can be recommended over another. It is important that each center adopt guidelines of routine assessment for the detection of pain and provide staff training in the use of the selected pain assessment tool.</p><p>Observational assessment may underestimate pain severity compared with self-reporting. This was illustrated in a study of young children (three to seven years of age) following surgery, in whom pain severity obtained by observational assessment was lower than that obtained by self-reporting [<a href="#rid20">20</a>].</p><p>Behavioral measurement of pain must also be assessed in the context of other sources of distress, such as hunger or anxiety [<a href="#rid21">21</a>]. In addition, parental response to the child's pain can impact the child's behavior.</p><p class="headingAnchor" id="H73565207"><span class="h3">Nonverbal children with neurologic impairment</span><span class="headingEndMark"> — </span>Nonverbal children with neurologic impairment present unique challenges in evaluating the presence and severity of pain as they cannot self-report their pain. For many such children, pain can remain a frequent, recurrent problem that often remains undertreated without appropriate evaluation.</p><p>In this group of children, similar core pain behaviors are consistently identified and can be used to assess and identify pain. However, each child will display a unique set of responses and behaviors. This unique and variable expression necessitates input from a consistent care provider, often a parent, with knowledge of a child's typical behavior patterns at baseline and in response to painful and nonpainful (such as hunger) events.</p><p>Specific behaviors that are associated with pain in nonverbal children with neurologic impairment include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vocalizations (crying, moaning)</p><p class="bulletIndent1"><span class="glyph">●</span>Facial expression (grimacing)</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to be consoled</p><p class="bulletIndent1"><span class="glyph">●</span>Increased movement, tone and posture (arching, stiffening), and physiologic responses</p><p class="bulletIndent1"><span class="glyph">●</span>In addition, some children display atypical behaviors such as laughing, becoming withdrawn, increased aggression, or lack of facial expression</p><p></p><p>Although pain assessment tools cannot replace the input of a parent or caregiver involved with the child on a daily basis, these tools can supplement the information from the parent/caregiver and assist with monitoring by assessing severity prior to an intervention to treat pain. The pain assessment tools for nonverbal children with neurologic impairment include the r-FLACC scale and the INRS [<a href="#rid14">14,18</a>]. These scales can be individualized by indicating behaviors specific to each child, with examples provided. This ability to add specific behaviors is an important feature for children with atypical pain behaviors that are not present in the other tools.</p><p class="headingAnchor" id="H426231772"><span class="h3">Impact on daily life</span><span class="headingEndMark"> — </span>Pain can impact participation in school, activities, sports, and relationships. Identifying this impact can then guide goals of management of chronic pain conditions. In chronic pain conditions, improvement in such areas is more meaningful than routine measurement of pain intensity.</p><p class="headingAnchor" id="H8"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>The main goals of pediatric pain management are to reduce, control, and prevent pain. Management varies depending upon the type, source, severity, and duration of pain. In some cases, treating the underlying source of pain or other related symptoms, such as distress or anxiety, can relieve the symptom. Even if specific therapy is available to treat the underlying source of pain, it is important to also provide adequate therapy to relieve any pain and suffering.</p><p class="headingAnchor" id="H1670058565"><span class="h2">General principles</span><span class="headingEndMark"> — </span>General principles of pain management in children include the following [<a href="#rid22">22-29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Regular pain assessments should be made throughout the course of treatment; self-reports should be obtained whenever possible. If the child is not able to self-report, an appropriate validated observational tool should be used (eg, r-FLACC  (<a class="graphic graphic_table graphicRef81819" href="/d/graphic/81819.html" rel="external">table 1</a>)). It is important to base management decisions on an accurate assessment of the child's pain. For children with chronic pain, the clinician should assess the degree to which it interferes with daily functioning (eg, participation in school and other activities). (See <a class="local">'Severity assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain management includes both nonpharmacologic and pharmacologic measures. Nonpharmacologic measures (eg, cognitive, behavioral, physical, and supportive therapies) should be provided for children undergoing painful procedures and/or those who require pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral analgesics should be used when possible to avoid painful routes of administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Side effects of analgesic agents should be anticipated and treated appropriately (eg, pruritus and/or constipation with opioids).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant therapy can be helpful in certain clinical settings (eg, anticonvulsants for neuropathic pain, antidepressants or anxiolytics for coexisting mood disturbances). (See <a class="local">'Adjuvant agents'</a> below.)</p><p></p><p>Clinicians who care for children at risk for pain should develop a consistent approach to the management of pediatric pain that is modifiable based upon the clinical setting. Important considerations include [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Type and duration of pain</p><p class="bulletIndent1"><span class="glyph">●</span>Patient's current pain medication regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Prior experience with pain medications, including adverse effects</p><p class="bulletIndent1"><span class="glyph">●</span>Parental experience and fears regarding the use of pain medications</p><p class="bulletIndent1"><span class="glyph">●</span>Previous use of nonpharmacologic interventions</p><p class="bulletIndent1"><span class="glyph">●</span>Child's coping skills</p><p class="bulletIndent1"><span class="glyph">●</span>Social, cultural, and spiritual factors</p><p></p><p class="headingAnchor" id="H1971786901"><span class="h2">Referral</span><span class="headingEndMark"> — </span>Referral to a pain specialist or palliative care team can be helpful in managing patients with pain that is chronic and/or difficult to control. For hospitalized patients, many institutions have policies in place to guide referral to inpatient pain teams. For example, pain service consultation is often automatically triggered when epidural or patient-controlled analgesia is used or for postoperative pain management.</p><p>Other reasons for referral to pain teams include assessment and management of chronic pain conditions that interfere with attendance in school and participation in activities. Pain has both a physical and psychological effect on children and parents. Social workers, child life specialists, and psychologists should be consulted to support the child and the family. Referral to palliative care teams can be particularly beneficial when pain occurs in the setting of a life-limiting condition. Such teams can assist with pain management, decision-making, and psychosocial support. (See  <a class="medical medical_review" href="/d/html/6252.html" rel="external">"Pediatric palliative care"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions for pain management include:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical measures, such as massage, heat and cold stimulation, and acupuncture</p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral measures, such as exercise, operant conditioning, relaxation, biofeedback, desensitization, and art and play therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive measures, such as distraction, imagery, hypnosis, and psychotherapy</p><p></p><p>Nonpharmacologic measures are particularly useful in reducing stress and anxiety in children undergoing invasive procedures. In a meta-analysis of 39 randomized clinical trials evaluating various psychological interventions for needle-related procedural pain in children, distraction and hypnosis significantly reduced pain and stress [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">PHARMACOLOGIC THERAPY</span></p><p class="headingAnchor" id="H1389605264"><span class="h2">Analgesic strategy based on pain severity</span><span class="headingEndMark"> — </span>The choice of analgesic medication depends upon the pain intensity and the child's response to previously administered agents:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild pain – Mild pain can generally be adequately treated with <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs) (see <a class="local">'Nonopioid analgesics'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe pain – Moderate to severe pain is generally treated with opioid agents, often in combination with nonopioid analgesics (see <a class="local">'Opioids'</a> below)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Nonopioid analgesics</span><span class="headingEndMark"> — </span>Nonopioid analgesics include <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and NSAIDs. <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">Aspirin</a> use has declined since the 1970s because of its association with Reye syndrome.</p><p>Nonopioid analgesics are effective for treatment of mild pain; they can also be used in combination with opioids to treat moderate and severe pain.</p><p class="headingAnchor" id="H14"><span class="h3">Acetaminophen</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">Acetaminophen</a> can be administered orally, rectally, or intravenously (IV). The oral dose of acetaminophen is 10 to 15 mg/kg every four to six hours (not to exceed five doses in 24 hours; maximum daily dose 75 mg/kg/day [not to exceed 4000 mg/day]). Rectal acetaminophen can be given at doses of10 to 20 mg/kg every four to six hours (not to exceed five doses in 24 hours; maximum daily dose 75 mg/kg/day [not to exceed 4000 mg/day]).</p><p>IV <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> dosing is based on age and weight of the patient, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants and children &lt;2 years – 7.5 to 15 mg/kg/dose every six hours (maximum daily dose 60 mg/kg/day)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children ≥2 years and adolescents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;50 kg – 15 mg/kg/dose every six hours or 12.5 mg/kg/dose every four hours (maximum single dose 750 mg; maximum daily dose 75 mg/kg/day [not to exceed 3750 mg/day])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥50 kg – 1000 mg every six hours or 650 mg every four hours (maximum daily dose 4000 mg/day)</p><p></p><p>Dosing errors have been reported with use of IV <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> in children [<a href="#rid32">32</a>]. This issue is discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Iatrogenic intravenous overdose'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">Ibuprofen</a> is the most commonly used NSAID in children. The dose of oral ibuprofen for pain reduction is 4 to 10 mg/kg every six to eight hours (maximum daily dose 40 mg/kg/day). Other commonly used nonselective NSAIDS include <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a>, <a class="drug drug_pediatric" data-topicid="12630" href="/d/drug information/12630.html" rel="external">naproxen</a>, <a class="drug drug_pediatric" data-topicid="13380" href="/d/drug information/13380.html" rel="external">indomethacin</a>, and <a class="drug drug_pediatric" data-topicid="13402" href="/d/drug information/13402.html" rel="external">ketorolac</a> (the latter is given IV and is particularly useful in the emergency department and inpatient settings). Selective cyclooxygenase-2 (COX-2) inhibitors are used less commonly in children.</p><p>Because of their antiinflammatory properties, NSAIDs may be more effective than <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> for pain reduction in inflammatory conditions (eg, systemic juvenile idiopathic arthritis). (See  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Nonsteroidal antiinflammatory drugs'</a>.)</p><p>Adverse events associated with NSAID use, particularly chronic use, include gastrointestinal bleeding and kidney toxicity. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Opioids</span><span class="headingEndMark"> — </span>Opioids are generally used in children with moderate or severe pain or pain that is refractory to nonopioid analgesics. They are most commonly used for pain relief following surgery or associated with specific conditions, such as sickle cell disease or cancer. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a> and  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease", section on 'Overview of acute pain management'</a> and  <a class="medical medical_review" href="/d/html/94561.html" rel="external">"Pharmacologic management of acute perioperative pain in infants and children", section on 'Opioids'</a>.)</p><p>Opioids reduce pain by interacting with one or more of the opiate receptors in the central nervous system  (<a class="graphic graphic_table graphicRef52205" href="/d/graphic/52205.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3883421733"><span class="h3">Opioid prescribing precautions</span><span class="headingEndMark"> — </span>Opioid prescription requires individual expertise and systems that adequately monitor safe use so as to minimize the risks of addiction and withdrawal. When managing acute pain, opioids should be prescribed in no greater quantity than what required for the expected duration of pain. For most painful conditions unrelated to major surgery or trauma, a three-day supply is sufficient. When opioids are prescribed postoperatively, the amount prescribed should be tailored to the expected intensity and duration of pain for the specific procedure. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/94561.html" rel="external">"Pharmacologic management of acute perioperative pain in infants and children", section on 'Postdischarge analgesia with opioids'</a>.)</p><p>Other considerations include informing the family/caregivers to store opioids in a safe location (ideally, in a locked cabinet) to reduce the risk of accidental overdose by other children and discourage diversion of opioids for illicit use. Unsafe practices regarding use, storage, and disposal of opioids prescribed to children are common [<a href="#rid33">33,34</a>].</p><p>Chronic pain is ideally managed by a team with expertise in all modalities of management, including nonpharmacologic and nonopioid medications, so as to minimize chronic use of opioids. When opioids are used, contracts can be drafted and signed by parents stating that they will request the medication from a single provider. The need for such steps should not be a barrier to opioid use in individuals receiving palliative care for life-limiting conditions. (See  <a class="medical medical_review" href="/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Opioid agreement/consent form'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Choice of opioid</span><span class="headingEndMark"> — </span>The choice of opioid is based upon the intensity and duration of pain, preferred mode of administration, associated adverse effects, prior experience (if available), and preference of the patient and family. For children with acute pain who are opioid-naïve, short-acting agents are generally preferred over long-acting or extended-release preparations. Oral agents are used for pain of moderate severity if the patient is able to tolerate oral medication. IV opioids may be warranted for severe acute pain. For chronic severe pain, a sustained-release preparation (eg, OxyContin or transdermal <a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">fentanyl</a>) or agents with a long half-life (eg, oral <a class="drug drug_pediatric" data-topicid="12590" href="/d/drug information/12590.html" rel="external">methadone</a>) may be used. </p><p class="headingAnchor" id="H18"><span class="h3">Specific agents</span><span class="headingEndMark"> — </span>A comprehensive discussion of all opioids used in the management of pain in children is beyond the scope of this topic. Commonly used agents are listed below; the initial doses and route of administrations are presented in the table  (<a class="graphic graphic_table graphicRef79047" href="/d/graphic/79047.html" rel="external">table 3</a>) [<a href="#rid6">6,30,35</a>]. Additional information is available in Lexicomp.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">Morphine</a> is the most commonly used opioid in children with moderate to severe pain because of its demonstrated efficacy and relative safety [<a href="#rid30">30</a>]. Morphine is available in oral, sublingual, subcutaneous, IV, rectal, and intrathecal preparations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13364" href="/d/drug information/13364.html" rel="external">Hydromorphone</a> has similar properties to <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a> but is more lipid-soluble, which may increase its potency. It also has slightly more rapid onset. Anecdotally, hydromorphone is often perceived as causing fewer side effects (eg, pruritus, gastrointestinal upset) compared with morphine; however, data supporting these advantages are generally lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12666" href="/d/drug information/12666.html" rel="external">Oxycodone</a> has similar properties to <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a> but is more potent and has a slightly longer half-life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">Hydrocodone</a> has similar potency as <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a>. It is often prescribed in combination with <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> (<a class="drug drug_pediatric" data-topicid="13359" href="/d/drug information/13359.html" rel="external">hydrocodone-acetaminophen</a>). If this preparation is used, caregivers should be instructed not to give the child other acetaminophen-containing medications, as this can lead to acetaminophen overdose and hepatotoxicity. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Inappropriate dosing by a caregiver'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">Fentanyl</a> has some unique properties that make it a useful opioid in pediatric pain control. IV fentanyl has a shorter onset and duration of action than <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a>, which makes it particularly useful in children undergoing invasive procedures who require conscious sedation and analgesia. (See  <a class="medical medical_review" href="/d/html/82857.html" rel="external">"Pediatric procedural sedation: Pharmacologic agents", section on 'Analgesic agents'</a>.)</p><p></p><p class="bulletIndent1">In addition, <a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">fentanyl</a> is the only opioid that is available in a transdermal form. The fentanyl patch has a long duration of action, which provides consistent and prolonged analgesia for children with chronic severe pain who are unable to take oral medications. Fentanyl patches cannot be used as the initial opioid for pain, because of its long onset of action, and cannot be used for acute or escalating pain, because its long half-life makes it difficult to titrate drug dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12590" href="/d/drug information/12590.html" rel="external">Methadone</a> requires less frequent administration compared with other opioids. Methadone is also available as an elixir that can be used as an extended analgesic agent in children who are unable to swallow pills. However, titration of methadone is complicated because of its rapid distribution (half-life two to three hours), followed by its slow variable elimination (half-life 4.2 to 130 hours) that may result in drug accumulation and toxicity two to five days after initiation or an increase in dose [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H3043002556"><span class="h3">Agents not recommended</span><span class="headingEndMark"> — </span>We suggest avoiding <a class="drug drug_pediatric" data-topicid="13178" href="/d/drug information/13178.html" rel="external">codeine</a> and <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a> in children &lt;12 years because of variability in metabolism that can alter the level of active drug the child is exposed to, resulting in fatal overdoses in extreme cases [<a href="#rid37">37-40</a>]. In children ≥12 years, caution should be used in prescribing these drugs, particularly in obese patients and those with obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems. These drugs should not be used for management of postoperative pain following tonsillectomy and/or adenoidectomy in children of any age [<a href="#rid41">41-43</a>]. (See  <a class="medical medical_review" href="/d/html/88054.html" rel="external">"Tonsillectomy (with or without adenoidectomy) in children: Postoperative care and complications", section on 'Pain'</a>.)</p><p>In 2017, the US Food and Drug Administration issued warnings and contraindications for the use of <a class="drug drug_pediatric" data-topicid="13178" href="/d/drug information/13178.html" rel="external">codeine</a> and <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a> for pain management in all children &lt;12 years old [<a href="#rid40">40</a>]. Similar warnings regarding codeine have been issued by other agencies, including Health Canada [<a href="#rid44">44</a>] and the European Medicines Agency [<a href="#rid45">45</a>].</p><p>Metabolism of <a class="drug drug_pediatric" data-topicid="13178" href="/d/drug information/13178.html" rel="external">codeine</a> and <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a> is genetically determined by the highly polymorphic enzyme P450 2D6 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F124030&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1QX49GWm%2BTSkdjo0hk63Tez&amp;TOPIC_ID=6254" target="_blank"><i>CYP2D6</i></a>) pathway. These drugs are ineffective in some children due to genetic polymorphisms in <em>CYP2D6</em> that cause poor metabolism of the drug [<a href="#rid46">46</a>]. Of even greater concern, a small portion of children may have increased conversion to active metabolites (ultrarapid-metabolizer phenotypes), which can lead to overdose [<a href="#rid37">37,38,46-49</a>].</p><p>There have been more pediatric fatalities reported in association with <a class="drug drug_pediatric" data-topicid="13178" href="/d/drug information/13178.html" rel="external">codeine</a> than with <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a>. The 2017 US Food and Drug Administration statement cited data from the adverse event reporting system from 1969 to 2015, during which time there were 64 cases reported worldwide of respiratory depression associated with codeine use in children, including 24 deaths [<a href="#rid40">40</a>]. During the same period, there were nine reported cases of respiratory depression associated with tramadol use in children, including three deaths. All three fatalities occurred outside the United States and involved tramadol oral drops, a formulation not available in the United States.</p><p>Determining which children are ultrarapid-metabolizers is difficult, making routine testing impractical. With any opioid, there is an increased chance of an overdose in overweight/obese children if dosing is based upon total body weight rather than lean mass since there is a lower distribution of <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a> to fatty tissue.</p><p class="headingAnchor" id="H19"><span class="h3">Initial dosing</span><span class="headingEndMark"> — </span>Dosing guidance for commonly used agents is summarized in the table  (<a class="graphic graphic_table graphicRef79047" href="/d/graphic/79047.html" rel="external">table 3</a>). The suggested doses are appropriate for opiate-naïve patients. As a general rule, short-acting agents should be used for treatment of acute pain. The opioid dose and interval are adjusted to obtain pain relief and avoid unacceptable side effects. The required dose varies with the severity of the pain, type of pain, and preexisting opioid tolerance.</p><p class="headingAnchor" id="H21"><span class="h3">Patient-controlled analgesia</span><span class="headingEndMark"> — </span>Patient-controlled analgesia is an option for adolescent and mature preadolescent children who are able to reliably assess their pain. For children who are not developmentally appropriate for patient-controlled analgesia (eg, because of young age or developmental disability), nursing-controlled analgesia with close monitoring is an option [<a href="#rid50">50-52</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/94561.html" rel="external">"Pharmacologic management of acute perioperative pain in infants and children", section on 'Patient-controlled analgesia in children'</a> and  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Patient-controlled analgesia'</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Opioid equivalence dosing</span><span class="headingEndMark"> — </span>When changing opioid agents, it is important to be familiar with equivalent analgesic dosing of the different opioids so that the desired analgesic effect can be maintained  (<a class="graphic graphic_table graphicRef79047" href="/d/graphic/79047.html" rel="external">table 3</a>). Opioid doses generally are expressed in parenteral <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a> equivalents. The unit opioid dose generally used is 10 mg of parenteral morphine, and doses of other drugs for oral or parenteral administration are listed in equianalgesic amounts.</p><p>When opioids are changed, the dose of the calculated equivalent analgesic dose of the new drug should be lowered by 25 to 50 percent and increased as needed. This avoids overmedication, which occurs due to differences in the structure of the different opioids and their affinity for the opiate receptors (ie, cross-tolerance).</p><p class="headingAnchor" id="H23"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>When treating pain with opioids, it is important to anticipate and manage their adverse effects to assure continued use. The following adverse effects of opioids and their management are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation and cognitive dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory depression</p><p class="bulletIndent1"><span class="glyph">●</span>Myoclonus and hyperalgesia</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus</p><p></p><p class="headingAnchor" id="H24"><span class="h3">Use in patients with kidney or liver disease</span><span class="headingEndMark"> — </span>In patients with kidney or hepatic impairment, side effects can occur more readily due to accumulation of metabolites, especially with <a class="drug drug_pediatric" data-topicid="12580" href="/d/drug information/12580.html" rel="external">meperidine</a>, <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a>, and <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a>. As previously discussed, tramadol is not recommended in pediatric patients regardless of kidney and liver function. (See <a class="local">'Agents not recommended'</a> above.)</p><p>In patients with impaired kidney function, <a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">fentanyl</a>, <a class="drug drug_pediatric" data-topicid="13364" href="/d/drug information/13364.html" rel="external">hydromorphone</a>, and <a class="drug drug_pediatric" data-topicid="12590" href="/d/drug information/12590.html" rel="external">methadone</a> are considered the safest opioids; <a class="drug drug_pediatric" data-topicid="12666" href="/d/drug information/12666.html" rel="external">oxycodone</a> and <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a> should be avoided or used with caution [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Patients with kidney impairment'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Adjuvant agents</span><span class="headingEndMark"> — </span>Adjuvant therapy can be used in any child with pain, regardless of the intensity. It can enhance analgesic efficacy, treat concurrent symptoms, and/or provide independent analgesic activity for specific types of pain. Adjuvant therapy is particularly helpful for neuropathic pain and chronic pain, including in children with cancer or with severe neurologic impairment. Consultation with a pain specialist or palliative care team can assist with use of these medications.</p><p>Adjuvant therapy in children includes the following classes of drugs, which are discussed in greater detail separately (see  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Antidepressants for neuropathic pain (eg, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants)</p><p class="bulletIndent1"><span class="glyph">●</span>Anticonvulsants for neuropathic pain (<a class="drug drug_pediatric" data-topicid="13330" href="/d/drug information/13330.html" rel="external">gabapentin</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids for hepatic distention and cerebral edema</p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates for bone pain due to tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy for bone pain due to tumor</p><p></p><p class="headingAnchor" id="H3380341503"><span class="h1">PAIN MANAGEMENT IN SPECIFIC CIRCUMSTANCES</span></p><p class="headingAnchor" id="H924223870"><span class="h2">Procedural pain</span><span class="headingEndMark"> — </span>For children undergoing invasive procedures, adequate pain management is a key component to procedural success. Pain management in this setting may include nonpharmacologic measures (eg, distraction), topical or local anesthetic therapy  (<a class="graphic graphic_table graphicRef117407" href="/d/graphic/117407.html" rel="external">table 4</a>), and/or systemic analgesic agents. Preparing the child prior to the intervention by describing the various steps can help decrease the stress and anxiety associated with the procedure. Pediatric procedural pain management is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach"</a> and  <a class="medical medical_review" href="/d/html/82857.html" rel="external">"Pediatric procedural sedation: Pharmacologic agents", section on 'Analgesic agents'</a>.)</p><p class="headingAnchor" id="H2035914458"><span class="h2">Perioperative pain</span><span class="headingEndMark"> — </span>Pediatric perioperative pain management is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/127173.html" rel="external">"Approach to the management of acute perioperative pain in infants and children"</a> and  <a class="medical medical_review" href="/d/html/94561.html" rel="external">"Pharmacologic management of acute perioperative pain in infants and children"</a>.)</p><p class="headingAnchor" id="H1879199226"><span class="h2">Sickle cell disease</span><span class="headingEndMark"> — </span>Management of pain in children with sickle cell disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H3625870044"><span class="h2">Cancer</span><span class="headingEndMark"> — </span>Management of chronic pain in patients with cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a> and  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a> and  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a>.)</p><p class="headingAnchor" id="H3476708652"><span class="h2">Functional abdominal pain</span><span class="headingEndMark"> — </span>Management of functional abdominal pain in children and adolescents is discussed separately. (See  <a class="medical medical_review" href="/d/html/112.html" rel="external">"Functional abdominal pain in children and adolescents: Management in primary care", section on 'Management of symptoms'</a>.)</p><p class="headingAnchor" id="H2200123983"><span class="h2">Chronic headaches</span><span class="headingEndMark"> — </span>Management of chronic headaches in children is discussed separately (See  <a class="medical medical_review" href="/d/html/2842.html" rel="external">"Headache in children: Approach to evaluation and general management strategies", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1867947174"><span class="h2">Burn pain</span><span class="headingEndMark"> — </span>Management of pain in patients with severe burns is discussed separately. (See  <a class="medical medical_review" href="/d/html/16505.html" rel="external">"Paradigm-based treatment approaches for management of burn pain"</a>.)</p><p class="headingAnchor" id="H73565266"><span class="h2">Neurologic impairment</span><span class="headingEndMark"> — </span>Pain is a frequent and significant problem for children with neurologic impairment (eg, cerebral palsy), and it is often underrecognized and undertreated in this patient population [<a href="#rid55">55</a>]. Sources of nociceptive pain may include gastroesophageal reflux, urinary tract infection, bone fracture, hip dislocation/subluxation, dystonia, constipation, acute pancreatitis, and gallstones. In nonverbal children with neurologic impairment who present with apparent pain, an assessment for these causes is appropriate. (See  <a class="medical medical_review" href="/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features", section on 'Chronic pain'</a>.)</p><p>If no treatable cause is identified, an empirical trial of <a class="drug drug_pediatric" data-topicid="13330" href="/d/drug information/13330.html" rel="external">gabapentin</a> therapy can be initiated. Gabapentin can be beneficial in these children because it targets visceral hyperalgesia and central neuropathic pain [<a href="#rid3">3,4</a>]. Other medications that have been used to treat chronic pain in this setting include tricyclic antidepressants, <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a>, and opioids [<a href="#rid4">4,56</a>]. Given the complexities of assessing pain in children with neurologic impairment and the need for ongoing adjustments in the care plan, often over many years, referral to a pediatric palliative care team is generally warranted.</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of pediatric pain includes (see <a class="local">'Evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Characterizing the type of pain (nociceptive versus neuropathic) (see <a class="local">'Types of pain'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Identifying its source and location (see <a class="local">'Source and location'</a> above and <a class="local">'Pain location tools'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Assessing the severity and its psychological impact (see <a class="local">'Severity assessment'</a> above and <a class="local">'Impact on daily life'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity assessment</strong> – The approach to assessing the severity of pediatric pain depends upon the child's cognitive ability (see <a class="local">'Severity assessment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Self-reporting is used in children who are able to understand and report their pain severity along a continuum (eg, visual analog scales, FACES scale  (<a class="graphic graphic_figure graphicRef51021" href="/d/graphic/51021.html" rel="external">figure 2</a>)). (See <a class="local">'Self-reporting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In infants and children who are unable to perform self-reporting, behavioral observational scales are used (eg, revised Face, Legs, Activity, Cry, Consolability [r-FLACC] tool  (<a class="graphic graphic_table graphicRef81819" href="/d/graphic/81819.html" rel="external">table 1</a>)). It is important to recognize that parental response to the child's pain can impact the child's behavior. (See <a class="local">'Observational tools'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain assessment in nonverbal children with neurologic impairment is challenging because they are unable to self-report. However, observational tools based on behavioral response including input from daily caregivers (eg, parents) are helpful in the assessment of pain in this group of children. (See <a class="local">'Nonverbal children with neurologic impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The goal of pediatric pain management is to reduce, control, or prevent pain in children. Pain management varies depending upon the type, source, severity, and duration of pain. General principles of pain management in children include the following (see <a class="local">'Overview of management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regular pain assessments should be made throughout the course of treatment. (See <a class="local">'Severity assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain management includes both nonpharmacologic and pharmacologic measures. Nonpharmacologic therapy (eg, cognitive, behavioral, physical, and supportive therapies) should be provided for children undergoing painful procedures and/or those who require pharmacologic therapy. (See <a class="local">'Nonpharmacologic interventions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild pain can generally be adequately treated with <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs (NSAIDs). (See <a class="local">'Nonopioid analgesics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe pain is generally treated with opioid agents (eg, <a class="drug drug_pediatric" data-topicid="16024" href="/d/drug information/16024.html" rel="external">morphine</a>, <a class="drug drug_pediatric" data-topicid="13364" href="/d/drug information/13364.html" rel="external">hydromorphone</a>, <a class="drug drug_pediatric" data-topicid="12666" href="/d/drug information/12666.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>, <a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">fentanyl</a>, <a class="drug drug_pediatric" data-topicid="12590" href="/d/drug information/12590.html" rel="external">methadone</a>)  (<a class="graphic graphic_table graphicRef79047" href="/d/graphic/79047.html" rel="external">table 3</a>). The choice of opioid is dependent upon the intensity and duration of pain, preferred mode of administration, associated adverse effects, previous experience (if available), and preference of the patient and family. (See <a class="local">'Opioids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral analgesics should be used when possible to avoid painful routes of administration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects of analgesic agents should be anticipated and treated appropriately (eg, pruritus and/or constipation with opioids). (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjuvant therapy can be helpful in certain clinical settings (eg, anticonvulsants for neuropathic pain, antidepressants or anxiolytics for coexisting mood disturbances). (See <a class="local">'Adjuvant agents'</a> above.)</p><p></p><p class="headingAnchor" id="H16463077"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Joanne Wolfe, MD, and Barbara Jones, PhD, MSW, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">International Association for the Study of Pain. IASP Terminology. 2017. Available at: https://www.iasp-pain.org/terminology?navItemNumber=576#Pain (Accessed on January 29, 2020).</li><li><a class="nounderline abstract_t">Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet 2021; 397:2098.</a></li><li><a class="nounderline abstract_t">Hauer JM, Wical BS, Charnas L. Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment. Pediatrics 2007; 119:e519.</a></li><li><a class="nounderline abstract_t">Hauer J. Identifying and managing sources of pain and distress in children with neurological impairment. Pediatr Ann 2010; 39:198.</a></li><li><a class="nounderline abstract_t">Friedrichsdorf SJ, Giordano J, Desai Dakoji K, et al. Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain Disorders in Head, Abdomen, Muscles and Joints. Children (Basel) 2016; 3.</a></li><li><a class="nounderline abstract_t">Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med 2002; 347:1094.</a></li><li><a class="nounderline abstract_t">Beyer JE, Denyes MJ, Villarruel AM. The creation, validation, and continuing development of the Oucher: a measure of pain intensity in children. J Pediatr Nurs 1992; 7:335.</a></li><li class="breakAll">Wong's Essentials of Pediatric Nursing, 6th ed, Wong DL, Hockenberry MJ, Winkelstein ML, et al (Eds), Mosby, 2001.</li><li><a class="nounderline abstract_t">Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988; 14:9.</a></li><li><a class="nounderline abstract_t">Tomlinson D, von Baeyer CL, Stinson JN, Sung L. A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010; 126:e1168.</a></li><li><a class="nounderline abstract_t">Hamill JK, Lyndon M, Liley A, Hill AG. Where it hurts: a systematic review of pain-location tools for children. Pain 2014; 155:851.</a></li><li><a class="nounderline abstract_t">Breau LM, Camfield C, McGrath PJ, et al. Measuring pain accurately in children with cognitive impairments: refinement of a caregiver scale. J Pediatr 2001; 138:721.</a></li><li><a class="nounderline abstract_t">Breau LM, McGrath PJ, Camfield CS, Finley GA. Psychometric properties of the non-communicating children's pain checklist-revised. Pain 2002; 99:349.</a></li><li><a class="nounderline abstract_t">Malviya S, Voepel-Lewis T, Burke C, et al. The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment. Paediatr Anaesth 2006; 16:258.</a></li><li><a class="nounderline abstract_t">Voepel-Lewis T, Merkel S, Tait AR, et al. The reliability and validity of the Face, Legs, Activity, Cry, Consolability observational tool as a measure of pain in children with cognitive impairment. Anesth Analg 2002; 95:1224.</a></li><li><a class="nounderline abstract_t">Hunt AM. A survey of signs, symptoms and symptom control in 30 terminally ill children. Dev Med Child Neurol 1990; 32:341.</a></li><li><a class="nounderline abstract_t">Hunt A, Burne R. Medical and nursing problems of children with neurodegenerative disease. Palliat Med 1995; 9:19.</a></li><li><a class="nounderline abstract_t">Solodiuk J, Curley MA. Pain assessment in nonverbal children with severe cognitive impairments: the Individualized Numeric Rating Scale (INRS). J Pediatr Nurs 2003; 18:295.</a></li><li><a class="nounderline abstract_t">Voepel-Lewis T, Malviya S, Tait AR, et al. A comparison of the clinical utility of pain assessment tools for children with cognitive impairment. Anesth Analg 2008; 106:72.</a></li><li><a class="nounderline abstract_t">Beyer JE, McGrath PJ, Berde CB. Discordance between self-report and behavioral pain measures in children aged 3-7 years after surgery. J Pain Symptom Manage 1990; 5:350.</a></li><li><a class="nounderline abstract_t">Berde C, Wolfe J. Pain, anxiety, distress, and suffering: interrelated, but not interchangeable. J Pediatr 2003; 142:361.</a></li><li><a class="nounderline abstract_t">McGrath PA. Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. J Pain Symptom Manage 1996; 12:87.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics. Committee on Psychosocial Aspects of Child and Family Health, Task Force on Pain in Infants, Children, and Adolescents. The assessment and management of acute pain in infants, children, and adolescents. Pediatrics 2001; 108:793.</a></li><li><a class="nounderline abstract_t">Fein JA, Zempsky WT, Cravero JP, et al. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2012; 130:e1391.</a></li><li><a class="nounderline abstract_t">Association of Paediatric Anaesthetists of Great Britain and Ireland. Good practice in postoperative and procedural pain management, 2nd edition. Paediatr Anaesth 2012; 22 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Stapelkamp C, Carter B, Gordon J, Watts C. Assessment of acute pain in children: development of evidence-based guidelines. Int J Evid Based Healthc 2011; 9:39.</a></li><li><a class="nounderline abstract_t">Taddio A, Appleton M, Bortolussi R, et al. Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline. CMAJ 2010; 182:E843.</a></li><li><a class="nounderline abstract_t">Guideline statement: management of procedure-related pain in children and adolescents. J Paediatr Child Health 2006; 42 Suppl 1:S1.</a></li><li class="breakAll">World Health Organization. Guidelines on the management of chronic pain in children. 2020. Available at: https://www.who.int/publications/i/item/9789240017870 (Accessed on January 15, 2021).</li><li><a class="nounderline abstract_t">Friedrichsdorf SJ, Kang TI. The management of pain in children with life-limiting illnesses. Pediatr Clin North Am 2007; 54:645.</a></li><li><a class="nounderline abstract_t">Uman LS, Birnie KA, Noel M, et al. Psychological interventions for needle-related procedural pain and distress in children and adolescents. Cochrane Database Syst Rev 2013; :CD005179.</a></li><li><a class="nounderline abstract_t">Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012; 129:349.</a></li><li><a class="nounderline abstract_t">Madden K, Reddy AS, De La Cruz MJ, et al. Patterns of Storage, Use, and Disposal of Prescription Opioids by Parents of Children With Cancer. J Pain Symptom Manage 2020; 59:320.</a></li><li><a class="nounderline abstract_t">Lawrence AE, Carsel AJ, Leonhart KL, et al. Effect of Drug Disposal Bag Provision on Proper Disposal of Unused Opioids by Families of Pediatric Surgical Patients: A Randomized Clinical Trial. JAMA Pediatr 2019; 173:e191695.</a></li><li><a class="nounderline abstract_t">Greco C, Berde C. Pain management for the hospitalized pediatric patient. Pediatr Clin North Am 2005; 52:995.</a></li><li><a class="nounderline abstract_t">Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5:127.</a></li><li><a class="nounderline abstract_t">Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009; 361:827.</a></li><li><a class="nounderline abstract_t">Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012; 129:e1343.</a></li><li><a class="nounderline abstract_t">Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics 2015; 135:e753.</a></li><li class="breakAll">US Food and Drug Administration Drug Safety Communications. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf (Accessed on April 24, 2017).</li><li><a class="nounderline abstract_t">Mitchell RB, Archer SM, Ishman SL, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg 2019; 160:S1.</a></li><li><a class="nounderline abstract_t">Tan GX, Tunkel DE. Control of Pain After Tonsillectomy in Children: A Review. JAMA Otolaryngol Head Neck Surg 2017; 143:937.</a></li><li><a class="nounderline abstract_t">Prows CA, Zhang X, Huth MM, et al. Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. Laryngoscope 2014; 124:1242.</a></li><li class="breakAll">Health Canada. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php?_ga=1.144008432.418636605.1493064052 (Accessed on August 01, 2016).</li><li class="breakAll">European Medicines Agency. Codeine not to be used in children below 12 years for cough and cold. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500186162.pdf (Accessed on April 27, 2015).</li><li class="breakAll">Dean L. Medical Genetics Summaries, Pratt VM, Scott SA, Pirmohamed M, et al (Eds), National Center for Biotechnology Information (US), 2012.</li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm313631.htm (Accessed on February 12, 2013).</li><li class="breakAll">US Food and Drug Administration. Codeine Use in Certain Children After Tonsillectomy and/or Adenoidectomy: Drug Safety Communication - Risk of Rare, But Life-Threatening Adverse Events or Death. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm315627.htm (Accessed on August 15, 2012).</li><li><a class="nounderline abstract_t">Balyan R, Mecoli M, Venkatasubramanian R, et al. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics 2017; 18:337.</a></li><li><a class="nounderline abstract_t">Czarnecki ML, Salamon KS, Jastrowski Mano KE, et al. A preliminary report of parent/nurse-controlled analgesia (PNCA) in infants and preschoolers. Clin J Pain 2011; 27:102.</a></li><li><a class="nounderline abstract_t">Czarnecki ML, Ferrise AS, Jastrowski Mano KE, et al. Parent/nurse-controlled analgesia for children with developmental delay. Clin J Pain 2008; 24:817.</a></li><li><a class="nounderline abstract_t">Monitto CL, Greenberg RS, Kost-Byerly S, et al. The safety and efficacy of parent-/nurse-controlled analgesia in patients less than six years of age. Anesth Analg 2000; 91:573.</a></li><li><a class="nounderline abstract_t">Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005; 33:311.</a></li><li><a class="nounderline abstract_t">Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.</a></li><li><a class="nounderline abstract_t">Hauer J, Houtrow AJ, SECTION ON HOSPICE AND PALLIATIVE MEDICINE, COUNCIL ON CHILDREN WITH DISABILITIES. Pain Assessment and Treatment in Children With Significant Impairment of the Central Nervous System. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Hauer J. Improving comfort in children with severe neurological impairment. Prog Palliat Care 2012; 20:349.</a></li></ol></div><div id="topicVersionRevision">Topic 6254 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.iasp-pain.org/terminology?navItemNumber=576#Pain" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Association for the Study of Pain. IASP Terminology. 2017. Available at: https://www.iasp-pain.org/terminology?navItemNumber=576#Pain (Accessed on January 29, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062144" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nociplastic pain: towards an understanding of prevalent pain conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272610" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411897" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Identifying and managing sources of pain and distress in children with neurological impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27973405" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain Disorders in Head, Abdomen, Muscles and Joints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362012" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Analgesics for the treatment of pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1479552" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The creation, validation, and continuing development of the Oucher: a measure of pain intensity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1479552" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The creation, validation, and continuing development of the Oucher: a measure of pain intensity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344163" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pain in children: comparison of assessment scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921070" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A systematic review of faces scales for the self-report of pain intensity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24316444" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Where it hurts: a systematic review of pain-location tools for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343050" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Measuring pain accurately in children with cognitive impairments: refinement of a caregiver scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12237214" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Psychometric properties of the non-communicating children's pain checklist-revised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490089" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401598" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The reliability and validity of the Face, Legs, Activity, Cry, Consolability observational tool as a measure of pain in children with cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110086" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A survey of signs, symptoms and symptom control in 30 terminally ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7719515" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Medical and nursing problems of children with neurodegenerative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923744" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pain assessment in nonverbal children with severe cognitive impairments: the Individualized Numeric Rating Scale (INRS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165556" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison of the clinical utility of pain assessment tools for children with cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2269802" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Discordance between self-report and behavioral pain measures in children aged 3-7 years after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712049" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pain, anxiety, distress, and suffering: interrelated, but not interchangeable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8754986" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533354" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The assessment and management of acute pain in infants, children, and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109683" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relief of pain and anxiety in pediatric patients in emergency medical systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817132" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Good practice in postoperative and procedural pain management, 2nd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21332662" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Assessment of acute pain in children: development of evidence-based guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098062" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626312" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Guideline statement: management of procedure-related pain in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626312" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guideline statement: management of procedure-related pain in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17933616" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The management of pain in children with life-limiting illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108531" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Psychological interventions for needle-related procedural pain and distress in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271694" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravenous acetaminophen in the United States: iatrogenic dosing errors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562890" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patterns of Storage, Use, and Disposal of Prescription Opioids by Parents of Children With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31233129" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of Drug Disposal Bag Provision on Proper Disposal of Unused Opioids by Families of Pediatric Surgical Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009254" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pain management for the hospitalized pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839235" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Methadone use in cancer patients with pain: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692698" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Codeine, ultrarapid-metabolism genotype, and postoperative death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492761" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : More codeine fatalities after tonsillectomy in North American children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25647677" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25647677" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798778" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical Practice Guideline: Tonsillectomy in Children (Update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28662233" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Control of Pain After Tonsillectomy in Children: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122716" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28244808" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842021" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A preliminary report of parent/nurse-controlled analgesia (PNCA) in infants and preschoolers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936600" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Parent/nurse-controlled analgesia for children with developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960379" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The safety and efficacy of parent-/nurse-controlled analgesia in patients less than six years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973913" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute pain management pharmacology for the patient with concurrent renal or hepatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504625" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Opioids in renal failure and dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562301" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pain Assessment and Treatment in Children With Significant Impairment of the Central Nervous System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Improving comfort in children with severe neurological impairment</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
